Investment Thesis
Cyclerion is a pre-commercial pharmaceutical company with zero revenue, significant operating losses of $3.2M, and negative free cash flow of $1.2M, indicating failed or stalled product development. With only $2.8M in cash and a burn rate of ~$1.2M annually, the company has approximately 2-3 years of runway before requiring dilutive financing. The absence of any commercial revenue generation in a pharmaceutical context suggests either failed clinical trials or products stuck in development.
Strengths
- No long-term debt (0.00x debt-to-equity ratio)
- Current ratio of 1.80x indicates adequate short-term liquidity
- Cash reserves of $2.8M provide near-term operational cushion
Risks
- Zero revenue indicates no commercialized products or failed market entry
- Annual cash burn of $1.2M with only 2-3 years of runway remaining
- Negative ROE (-46.8%) and ROA (-37.4%) reflect fundamental unprofitability
- No insider activity in past 90 days suggests low confidence from management
- Limited cash runway necessitates additional capital raises, likely dilutive to shareholders
Key Metrics to Watch
- Cash burn rate and months of runway remaining
- Clinical trial progress and regulatory milestone achievements
- Timing and success of product commercialization events
- Capital raise activities and dilution impact
- Operating expense trends relative to pipeline advancement
Financial Metrics
Revenue
0.0
Net Income
-3.2M
EPS (Diluted)
$-0.76
Free Cash Flow
-1.2M
Total Assets
8.5M
Cash
2.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-46.8%
ROA
-37.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.80x
Quick Ratio
1.80x
Debt/Equity
0.00x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T06:52:05.651184 |
Data as of: 2026-03-31 |
Powered by Claude AI